Optimizing Frontline Therapy in Ovarian Cancer Using PARP Inhibitors: A Video Roundtable

Download this slideset from an expert roundtable discussion covering the latest insights on PARP inhibitors for frontline maintenance treatment in patients with ovarian cancer.

This educational activity is intended for clinicians practicing medicine outside of the United States.

Nicoletta Colombo, MD
Thomas J. Herzog, MD
Ignace Vergote, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 4.68 MB
Released: May 21, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This educational activity is supported by an educational grant from
GlaxoSmithKline

Related Content

From Clinical Care Options (CCO), download a PDF featuring expert discussion on patient cases on ovarian cancer treatment

Nicoletta Colombo, MD person default Philipp Harter, MD, PhD person default Alexandra Leary, MD, PhD Released: October 19, 2021

A downloadable slideset from Clinical Care Options (CCO) developed by 3 expert faculty on the expert management of ovarian cancer using PARP inhibitors.

Ursula Matulonis, MD
Program Director
Robert L. Coleman, MD, FACOG, FACS person default Kathleen Moore, MD
Released: October 18, 2021

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Virtual presentation by Eloise Chapman-Davis, MD, FACOG, on individualizing care for women with ovarian cancer based on current and emerging clinical data, from Clinical Care Options (CCO)

Eloise Chapman-Davis, MD, FACOG Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: October 15, 2021 Expired: October 14, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue